BACK of the BOOK
Heard in the Blogosphere
ASH The Race to Publish in Worthless Journals
Cuts to @NIH hurt biomedical research & our ability
to conquer blood diseases. That’s why we’re urging
Congress to #RaisetheCaps! #CutsHurt In academic medicine, the term “predatory journals” refers to journals
that take advantage of unsuspecting, well-meaning researchers –
charging authors high article-processing fees in exchange for another
publication to add to their CVs. However, some experts believe the
relationship has become less “predator and prey” and more a willing
symbiosis. In The New York Times, authors and researchers shared
their opinions on the dangers of the “publish or perish” academic
environment that fuels this ongoing problem.
@ASH_hematology
Jay Bradner, MD
@jaybradner
I find there are 2 types of nerds: planet/moon and
gene/atom. Firmly in the latter category, back to the
total eclipse of disease ...
Sara Jiang, MD
“When hundreds of thousands of publications appear in predatory
journals, it stretches credulity to believe all the authors and
universities they work for are victims.”
—Derek Pyne, PhD, an economics professor at Thompson Rivers University in British Columbia
@Sara_Jiang
ortune cookie pressure #writeabook
F
#academicfortunes
“[The motivation behind publishing in predatory journals] is a touchy
subject. If you were tricked by spam email you might not want to
admit it, and if you did it wittingly to increase your publication counts
you might also not want to admit it.”
—Katarzyna Pisanski, PhD-C, a psychologist at the University of Sussex in England
“If something gets published in one of these journals and it’s complete
garbage, it can develop a life of its own. Think about human medicine
and how much is on the line. When people publish something that is
not replicable, it can have health impacts.”
—Dewayne Fox, PhD, an associate professor in the department of agriculture and natural resources
at Delaware State University
Adam Cifu, MD
@adamcifu
Someday we’ll replace silly names (conventional,
traditional, alternative, integrative) with “effective
medicine” & “ineffective medicine.”
Justin B. Dimick, MD, MPH
@jdimick1
ne of our @UM_IHPI research fellows, @leejs5,
O
asked all the other fellows for 3 words that describe
a great mentor. Here are the results:
Removing Barriers to High-Cost Cancer
Drugs
“The company that developed [tisagenlecleucel] is offering to
refund the money if it doesn’t work within a month. … This unusual
arrangement, a type of value-based or outcomes-based contract,
could be a template for similar deals over many innovative, high-cost
drugs, [but] value-based contracting alone isn’t likely to be the sole
solution to the coming tidal wave of innovative, high-cost treatments.
… Alternative approaches to financing them are needed, especially for
public programs like Medicare and Medicaid. Congress should require
the National Academy of Medicine to study alternatives and report
back on options. After all, there are problems worse than coping with
the coming wave of high cost, often highly e